3/27/2013

Sanofi and Transgene will invest $12.9 million to create a new industrial platform for immunotherapy production. The platform will belong to Sanofi. Sanofi and Genzyme will use the platform to manufacture clinical and commercial batches of Transgene's MVA1 therapeutic vaccines and other immunotherapy products.

Related Summaries